{"name":"PDC*line Pharma SAS","slug":"pdc-line-pharma-sas","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Keytruda Injectable Product","genericName":"Keytruda Injectable Product","slug":"keytruda-injectable-product","indication":"Non-small cell lung cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Alimta Injectable Product","genericName":"Alimta Injectable Product","slug":"alimta-injectable-product","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Keytruda Injectable Product","genericName":"Keytruda Injectable Product","slug":"keytruda-injectable-product","phase":"phase_2","mechanism":"PD-1 inhibitor","indications":["Non-small cell lung cancer","Melanoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Alimta Injectable Product","genericName":"Alimta Injectable Product","slug":"alimta-injectable-product","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNVExYR0dSdTlQLW5fZmhJRTRWNmEyRUp2ZkU5LVpQUWdNbng2SE9XaENKNjFkSmdTelpEUVExWXFveFB6TlZXMkZ1Y2U0MXZsRFZRUkVFZEdjaWhfMkMtODA2eWE4dmRRaEZzUy1XOVRXekFFVS1lQXR4dU1XQUlKWm1oVjM3NEY3VXJvQ2o5QXMxc0RVREpBbllFMm01N2hQUnlja1B2b1BSZWlqTmlKU05XT0Jmb3VSWEtCdFl1Q294dnpqSlgyOHgtTFZGYmtCVC12Y2Y1V3FnMFFBMWVmcUVZaVV2WVVqOXVjRU93cGRaMVBadnVIUHBHLUZtZ1N1Y0ktX0tKaUpLTTJPd1VaT212UF9iZ1UxTEZMOXFVUERUYnRIZk5TV2hR?oc=5","date":"2025-08-18","type":"pipeline","source":"GlobeNewswire","summary":"PD-(L)1 Inhibitors Market Set to Surge During the Forecast - GlobeNewswire","headline":"PD-(L)1 Inhibitors Market Set to Surge During the Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNQUNvVmRPVG1uNGljYzQ1S050dUdBdzh5dDM1UkV3dkFGd0ZyWWd6ejV0YnowM29yRVVxTVd3VURkM1JPRzl5MHNTV1hnemR1V2RiSDJSSzBldk5vc2t4TUhaRGE4b3p3blVyQXVIVHVxMzU4UW1ZT195TjU0SEUzZnkzSmhDa2ZsdXNvVEZkOGdVWW0zSmJQOWVPcl8ybDBQd2RjazRMaVF1R2poRThWbkdXSUZacDZ3ZmJuYWZ4b3lDdXZRY2FGY0IzTWM3TEFpY3g3b1NkWDZJMUZHRmJJdDFWMWxFSU5sQWxlRg?oc=5","date":"2024-12-12","type":"trial","source":"BioSpace","summary":"PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine at ESMO-IO 2024 - BioSpace","headline":"PDC*line Pharma Presents Primary Clinical Results From Phase I/II Trial on PDC*lung01 Cancer Vaccine at ESMO-IO 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNeVFYVF8zWDFMcjF4MGRWOUF6YXFCSUtCQUJlc2VGXzFiRTBqVnBhaF96ZlM5SlJyNU82bXhXQzBzZHRWM2JCZjc2V2pCeFl2SFV2aDNzZ0JOYTNXeklZeFFURTM2WXotMUJLM3l0a2hJNU1LaHYwb3RhSjQ5Q01fd3ExdmlhSUdFSlBHcFZKSQ?oc=5","date":"2024-02-05","type":"pipeline","source":"Frontiers","summary":"Extracorporeal Photopheresis: Tolerogenic or Immunogenic Cell Death? Beyond Current Dogma - Frontiers","headline":"Extracorporeal Photopheresis: Tolerogenic or Immunogenic Cell Death? Beyond Current Dogma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNaVMxZDh5Y3RHLVdWSW1rRXh3Rm84UklDcjRvNVk2RUl0dXFFT0FoV0VqNDYzQ3EwdmVuLWFrZHRmNDJIbWNhblp0Y2pGWU1BVlNpd19sbHEyNXR3OXc0cFFNVVRZa2JQcGhCZUpqTVVWWlVzTkFiUlBFWWJIWE1jNV9oeWVpSlF5ekM3dHhuTVRoX0dUdWM4Uk5lOHpPVWNWWDAxcHI0RFg0QzdGdWU5VlVCb2N3WnZqcmFpcm1FMk9pZnFyWXg4UWluVWUwd0M3RFFENVF0ZVczY0gzRFJRcko3aXA5REdobEstZ1ZlZ21BZlNsU3JRUUpVRzF2b2FyVmpiTnBZbkFOSzJYdUdFczhCR1lDN3d5alFOVzRUal83TDdMU2NmNkhIcDYzb00?oc=5","date":"2024-01-17","type":"deal","source":"Business Wire","summary":"PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Therapeutic Vaccine Project - Business Wire","headline":"PDC*line Pharma and Partners Receive €8.1M From Walloon Region and Wallonia Health Cluster BioWin for Personalized Thera","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}